Total Payments
$848,788
2023 Payments
$1,000
Companies
14
Transactions
182
Medicare Patients
3,958
Medicare Billing
$243,490
Payment Breakdown by Category
Research$573,660 (67.6%)
Consulting$270,861 (31.9%)
Other$3,400 (0.4%)
Travel$653.56 (0.1%)
Food & Beverage$212.94 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $573,660 | 105 | 67.6% |
| Consulting Fee | $270,861 | 69 | 31.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,400 | 2 | 0.4% |
| Travel and Lodging | $653.56 | 4 | 0.1% |
| Food and Beverage | $212.94 | 2 | 0.0% |
Payments by Type
Research
$573,660
105 transactions
General
$275,128
77 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $369,569 | 74 | $0 (2022) |
| Eli Lilly and Company | $163,100 | 20 | $0 (2022) |
| Allergan, Inc. | $103,840 | 6 | $0 (2020) |
| PFIZER INC. | $86,200 | 24 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $60,900 | 13 | $0 (2020) |
| Genentech, Inc. | $30,969 | 18 | $0 (2019) |
| Theravance Biopharma, Inc. | $8,100 | 6 | $0 (2018) |
| F. Hoffmann-La Roche AG | $5,700 | 4 | $0 (2021) |
| Celgene Corporation | $5,110 | 4 | $0 (2019) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $5,100 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,000 | 2 | Ferring Pharmaceuticals AS ($1,000) |
| 2022 | $74,600 | 17 | ABBVIE INC. ($36,100) |
| 2021 | $198,425 | 36 | ABBVIE INC. ($123,100) |
| 2020 | $362,984 | 48 | AbbVie Inc. ($147,144) |
| 2019 | $77,470 | 33 | AbbVie, Inc. ($26,825) |
| 2018 | $114,759 | 36 | AbbVie, Inc. ($32,600) |
| 2017 | $19,550 | 10 | Takeda Pharmaceuticals U.S.A., Inc. ($10,200) |
All Payment Transactions
182 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/28/2023 | Ferring Pharmaceuticals AS | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 05/17/2023 | Ferring Pharmaceuticals AS | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 05/05/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 05/04/2022 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies • Category: IMMUNOLOGY | ||||||
| 05/04/2022 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 • Category: IMMUNOLOGY | ||||||
| 05/04/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 05/04/2022 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $3,900.00 | Research |
| Study: A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease • Category: IMMUNOLOGY | ||||||
| 05/04/2022 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 05/04/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 01/28/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $20,100.00 | Research |
| Study: A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | ||||||
| 01/28/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $10,100.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | ||||||
| 01/28/2022 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $7,700.00 | Research |
| Study: A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) • Category: IMMUNOLOGY | ||||||
| 01/28/2022 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $6,300.00 | Research |
| Study: A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies • Category: IMMUNOLOGY | ||||||
| 01/28/2022 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $2,400.00 | Research |
| Study: A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 • Category: IMMUNOLOGY | ||||||
| 01/28/2022 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease • Category: IMMUNOLOGY | ||||||
| 01/28/2022 | Boehringer Ingelheim RCV GmbH & Co KG | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 01/28/2022 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 01/28/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 01/28/2022 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $300.00 | Research |
| Study: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy • Category: IMMUNOLOGY | ||||||
| 11/04/2021 | Boehringer Ingelheim RCV GmbH & Co KG | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 11/03/2021 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $12,300.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy • Category: IMMUNOLOGY | ||||||
| 11/03/2021 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $2,900.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 11/03/2021 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $300.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies • Category: IMMUNOLOGY | ||||||
| 07/29/2021 | ABBVIE INC. | RINVOQ (Biological) | — | Cash or cash equivalent | $6,300.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 07/29/2021 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $4,200.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease Who Failed Prior Biologic Treatment • Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $65,500 | 2 |
| M14-234 | AbbVie, Inc. | $55,400 | 9 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease Who Failed Prior Biologic Treatment | ABBVIE INC. | $49,100 | 3 |
| M14-234 | AbbVie Inc. | $44,200 | 4 |
| A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-Center Trial of Efficacy and Safety of Entyvio Vedolizumab in Subjects with Chronic Pouchitis | Takeda Pharmaceuticals U.S.A., Inc. | $37,500 | 10 |
| M14-675 | AbbVie Inc. | $27,200 | 4 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $26,700 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $24,600 | 2 |
| M15-991 | AbbVie Inc. | $24,000 | 2 |
| IN ACTIVE ULCERATIVE COLITIS, A RANDOMIZED CONTROLLED TRIAL FOR DETERMINATION OF THE OPTIMAL TREATMENT TARGET | Takeda Pharmaceuticals U.S.A., Inc. | $23,400 | 3 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $22,300 | 2 |
| M14-431 | AbbVie Inc. | $18,300 | 4 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy | ABBVIE INC. | $18,000 | 3 |
| A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY) | Eli Lilly and Company | $17,100 | 2 |
| M16-067 | AbbVie Inc. | $15,000 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $12,500 | 3 |
| A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | ABBVIE INC. | $12,300 | 2 |
| M14-433 | AbbVie Inc. | $10,500 | 4 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | Eli Lilly and Company | $7,900 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $7,800 | 1 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | ABBVIE INC. | $7,700 | 1 |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 | ABBVIE INC. | $6,900 | 2 |
| A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease | ABBVIE INC. | $5,700 | 2 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies | ABBVIE INC. | $3,900 | 3 |
| M14-675 | AbbVie, Inc. | $3,900 | 2 |
| TBPH0144 | Theravance Biopharma Inc. | $3,800 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 | ABBVIE INC. | $3,600 | 2 |
| TBPH0144 | Theravance Biopharma, Inc. | $3,600 | 2 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | ABBVIE INC. | $3,200 | 2 |
| A MULTICENTRE, RANDOMISED, DOUBLE-BLIND (SPONSOR-UNBLINDED), PLACEBO-C | GlaxoSmithKline, LLC. | $2,400 | 2 |
| A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $2,200 | 2 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis | ABBVIE INC. | $1,400 | 3 |
| PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) | Celgene Corporation | $1,144 | 1 |
| RPC01-202 - PhII UC Touchstone (RPC01-202) (BMS Study Number: IM047-P21) | Celgene Corporation | $1,082 | 1 |
| M14-431 | AbbVie, Inc. | $1,000 | 3 |
| RPC01-3201 - PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) | Celgene Corporation | $884.00 | 1 |
| TBPH0144_07112018 | Theravance Biopharma, Inc. | $700.00 | 1 |
| PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNF INHIBITORS. | F. Hoffmann-La Roche AG | $450.00 | 2 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | ABBVIE INC. | $300.00 | 1 |
| M14-433 | AbbVie, Inc. | $300.00 | 1 |
| M16-066 | AbbVie Inc. | $200.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 973 | 2,002 | $415,610 | $58,543 |
| 2022 | 12 | 1,042 | 2,276 | $456,710 | $68,264 |
| 2021 | 11 | 980 | 1,998 | $85,394 | $60,655 |
| 2020 | 10 | 963 | 1,839 | $93,187 | $56,028 |
Total Patients
3,958
Total Services
8,115
Medicare Billing
$243,490
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2023 | 245 | 535 | $125,725 | $15,298 | 12.2% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 126 | 351 | $83,045 | $9,678 | 11.7% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2023 | 80 | 99 | $27,720 | $6,234 | 22.5% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2023 | 41 | 41 | $29,725 | $4,564 | 15.4% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Office | 2023 | 53 | 53 | $30,210 | $3,808 | 12.6% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Office | 2023 | 31 | 39 | $10,920 | $2,397 | 22.0% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Office | 2023 | 40 | 107 | $14,445 | $2,326 | 16.1% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2023 | 70 | 87 | $13,920 | $2,322 | 16.7% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2023 | 44 | 228 | $11,400 | $2,113 | 18.5% |
| 88331 | Pathology examination of specimen during surgery, first tissue block | Facility | 2023 | 22 | 41 | $12,300 | $1,955 | 15.9% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2023 | 47 | 69 | $11,040 | $1,840 | 16.7% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 41 | 152 | $7,600 | $1,409 | 18.5% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2023 | 23 | 59 | $7,965 | $1,282 | 16.1% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Facility | 2023 | 17 | 17 | $9,690 | $1,101 | 11.4% |
| 88332 | Pathology examination of specimen during surgery, each additional tissue block | Facility | 2023 | 15 | 39 | $6,045 | $919.72 | 15.2% |
| 88329 | Pathology examination of specimen during surgery | Facility | 2023 | 19 | 19 | $6,175 | $521.55 | 8.4% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 13 | 17 | $2,295 | $347.31 | 15.1% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2023 | 35 | 37 | $4,070 | $323.01 | 7.9% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Office | 2023 | 11 | 12 | $1,320 | $104.76 | 7.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 317 | 956 | $211,220 | $27,315 | 12.9% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Office | 2022 | 79 | 91 | $25,480 | $5,719 | 22.4% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2022 | 62 | 83 | $23,240 | $5,214 | 22.4% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2022 | 42 | 44 | $28,600 | $4,964 | 17.4% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Office | 2022 | 67 | 69 | $36,225 | $4,875 | 13.5% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2022 | 79 | 141 | $31,020 | $4,120 | 13.3% |
About Dr. Rish Pai, MD
Dr. Rish Pai, MD is a Clinical Pathology/Laboratory Medicine healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/03/2009. The National Provider Identifier (NPI) number assigned to this provider is 1700024494.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rish Pai, MD has received a total of $848,788 in payments from pharmaceutical and medical device companies, with $1,000 received in 2023. These payments were reported across 182 transactions from 14 companies. The most common payment nature is "" ($573,660).
As a Medicare-enrolled provider, Pai has provided services to 3,958 Medicare beneficiaries, totaling 8,115 services with total Medicare billing of $243,490. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Pathology/Laboratory Medicine
- Other Specialties Anatomic Pathology
- Location Scottsdale, AZ
- Active Since 02/03/2009
- Last Updated 08/12/2025
- Taxonomy Code 207ZP0105X
- Entity Type Individual
- NPI Number 1700024494
Products in Payments
- SKYRIZI (Biological) $106,400
- RINVOQ (Drug) $100,200
- RINVOQ (Biological) $89,800
- Entyvio (Biological) $37,500
- Non-Covered Product (Drug) $33,219
- Rinvoq (Biological) $10,900
- Pipeline (Drug) $2,300
- HUMIRA (Biological) $2,200
- GED-0301 (Drug) $2,000
- Ozanimod (Drug) $1,966
- RPC-1063 (Drug) $1,144
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Pathology/Laboratory Medicine Doctors in Scottsdale
Dr. Leon Su, M.d, M.D
Clinical Pathology/Laboratory Medicine — Payments: $104,035
Clinical Pathology/Laboratory Medicine $104,035
Dr. Jill Adamski, Md, Phd, MD, PHD
Clinical Pathology/Laboratory Medicine — Payments: $7,099
Clinical Pathology/Laboratory Medicine $7,099
Dr. Yasmeen Butt, M.d, M.D
Clinical Pathology/Laboratory Medicine — Payments: $1,000
Clinical Pathology/Laboratory Medicine $1,000
Longwen Chen, M.d, M.D
Clinical Pathology/Laboratory Medicine — Payments: $35.47
Clinical Pathology/Laboratory Medicine $35.47
Theresa Kinard, Md, MD
Clinical Pathology/Laboratory Medicine — Payments: $17.75
Clinical Pathology/Laboratory Medicine $17.75
James Hernandez, M.d, M.D
Clinical Pathology/Laboratory Medicine
Clinical Pathology/Laboratory Medicine